PDF factsheet
      Z

cholesterol lowering intervention in acute coronary syndrome for early initiation, clinical trials results

atorvastatin versus placebo
MIRACL, 2001
Atorvastatin, 80 mg (early initiation)
versus
Placebo
unstable angina or non–Q-wave acute MIDouble blind
Follow-up duration: 1 and 4 months
Europe, North America, South Africa, and Australasia
atorvastatin versus pravastatin
PROVE IT - TIMI 22, 2004
80 mg of atorvastatin daily (intensive therapy).
versus
40 mg of pravastatin daily (standard therapy)
patients who had been hospitalized for an acute coronary syndrome within the preceding 10 daysdouble blind
Follow-up duration: 24 mo (18-36 mo)
UK, US, AUstralia, Italy, France, Germany, Spain, Canada
atorvastatin versus usual care
Colivicchi, 2002
Atorvastatin, 80 mg daily early initiation
versus
Usual care
unstable angina pectoris or non-Q-wave myocardial infarctionopen
Follow-up duration: 1, 3, and 6 months
Italy
ESTABLISH, 2004
Atorvastatin, 20 mg early initiation
versus
Usual care
patients with ACS undergoing emergency coronary angiography and percutaneous coronary interventionopen
Follow-up duration: 1, 4, and 6 months
Japan
ezetimibe versus placebo (on top statins)
IMPROVE-IT, 2014
NCT00202878
10 mg/day of ezetimibe and 40 mg/day of simvastatin
versus
simvastatin 40 mg/day
subjects with stabilized high-risk acute coronary syndrome double blind
Follow-up duration: 5.68 years
39 countries
fluvastatin versus placebo
LIPS (sub groups), 2002
Fluvastatin, 80 mg
versus
Placebo
patients with unstable angina and successful first percutaneous coronary interventiondouble blind
Follow-up duration: 1, 4, and 6 months
Europe, Canada, and Brazil
FLORIDA, 2002
Fluvastatin, 80 mg (early initiation)
versus
Placebo
patients with an AMI and total cholesterol of <6.5 mmol.ldouble blind
Follow-up duration: 1, 4, and 6 months
The Netherlands
pitavastatin versus atorvastatin
JAPAN ACS, 2009
NCT00242944
pitavastatin 4 mg daily
versus
atorvastatin 20mg daily
patients with acute coronary syndrome undergoing IVUS-guided percutaneous coronary intervention open
Follow-up duration: 8-12 months
Japan
pravastatin versus placebo
LAMIL, 1997
Pravastatin, 10-20 mg (starting at D3)
versus
Placebo
patients suffering an acute myocardial infarction double blind
Follow-up duration: 1 and 3 months
Belgium
RECIFE, 1999
Pravastatin, 40 mg
versus
Placebo
Patients with acute myocardial infarction or unstable angina and total cholesterol levels at admission >=5.2 mmol/L or LDL >=3.4 mmol/L double blind
Follow-up duration: 1.5 months
Canada
PAIS, 2001
Pravastatin, 40 mg (initiated within 48 hours of hospital admission)
versus
Placebo
patients with acute coronary syndromesdouble blind
Follow-up duration: 1 and 3 months
The Netherlands
PACT, 2004
Pravastatin, 20-40 mg within 24 hours of the onset of symptoms in
versus
Placebo
patients with unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction within 24 hours of the onset of symptomsdouble blind
Follow-up duration: 1 months
Australia
pravastatin versus usual care
L-CAD, 2000
Pravastatin, 20-40 mg (strating on average at D6)
versus
Usual care
patients with acute coronary syndrome open
Follow-up duration: 1, 4, and 6 months
Germany
PTT, 2002
Pravastatin, 40 mg
versus
Usual care
patients who underwent coronary balloon angioplasty of the infarct-related artery during the first month of acute myocardial infarctionopen
Follow-up duration: 1 and 6 months
Turkey
simvastatin versus placebo
A to Z, 2004
Simvastatin, 40-80 mg early initiation
versus
Placebo
patient with an acute coronary syndrome (ACS)Double aveugle
Follow-up duration: 4 months
41 countries

  Options


in first

in second

  Filter